Education
About Us
Working with TipRanks
Follow Us
Rafarma Pharmaceuticals (RAFA)
:RAFA
RAFA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.03 - $0.18
Previous CloseN/A
Volume11.40K
Average Volume (3M)31.66K
Market Cap
$10.16M
Enterprise ValueN/A
Total Cash (Recent Filing)$73.00K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)36.3
Beta0.24
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding93,167,000
10 Day Avg. Volume38,714
30 Day Avg. Volume31,662
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
RAFA FAQ
What was Rafarma Pharmaceuticals ’s price range in the past 12 months?
Rafarma Pharmaceuticals lowest stock price was $0.03 and its highest was $0.18 in the past 12 months.
What is Rafarma Pharmaceuticals ’s market cap?
Rafarma Pharmaceuticals ’s market cap is $10.16M.
When is Rafarma Pharmaceuticals ’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Rafarma Pharmaceuticals ’s earnings last quarter?
Currently, no data Available
Is Rafarma Pharmaceuticals overvalued?
According to Wall Street analysts Rafarma Pharmaceuticals ’s price is currently Overvalued.
Does Rafarma Pharmaceuticals pay dividends?
Rafarma Pharmaceuticals does not currently pay dividends.
What is Rafarma Pharmaceuticals ’s EPS estimate?
Rafarma Pharmaceuticals ’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rafarma Pharmaceuticals have?
Rafarma Pharmaceuticals has 93,167,000 shares outstanding.
What happened to Rafarma Pharmaceuticals ’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Rafarma Pharmaceuticals ?
Currently, no hedge funds are holding shares in RAFA
Company Description
Rafarma Pharmaceuticals
Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in Russia. It offers cephalosporin-based products, antibiotics of non-ß structure, and anti-cancer drugs in the form of injections, ampulla packaged products, child suspensions, tablets, and capsules. The company also provides drugs for accidental wounds, inflammatory eye diseases, and immunological disorders. The company has a collaboration agreement with PlantEXT Ltd. to research and manufacture the first medical cannabis suppositories for patients suffering from inflammatory bowel disease. Rafarma Pharmaceuticals, Inc. was formerly known as Johnston Acquisition Corp. and changed its name to Rafarma Pharmaceuticals, Inc. in October 2012. The company is based in Sandy, Utah with a manufacturing and distribution facility in Russia. As of October 19, 2020, Rafarma Pharmaceuticals, Inc. operates as a subsidiary of R. & D. Biocogency Laboratories Inc. Ltd.